Henry Schein, Inc. (NASDAQ:HSIC) Position Increased by ProShare Advisors LLC

ProShare Advisors LLC lifted its position in Henry Schein, Inc. (NASDAQ:HSIC) by 6.6% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 18,860 shares of the company’s stock after buying an additional 1,165 shares during the quarter. ProShare Advisors LLC’s holdings in Henry Schein were worth $1,209,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Henry Schein by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock worth $1,165,425,000 after buying an additional 260,537 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Henry Schein by 3.1% during the second quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock worth $351,543,000 after acquiring an additional 162,477 shares in the last quarter. Swedbank AB acquired a new stake in Henry Schein during the first quarter valued at $215,998,000. Fiduciary Management Inc. WI grew its stake in Henry Schein by 17.1% in the fourth quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock valued at $172,947,000 after purchasing an additional 333,855 shares in the last quarter. Finally, Nuance Investments LLC increased its position in Henry Schein by 6.2% in the 2nd quarter. Nuance Investments LLC now owns 1,863,333 shares of the company’s stock worth $119,440,000 after purchasing an additional 108,143 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Up 3.3 %

Shares of NASDAQ:HSIC opened at $73.22 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.55 and a debt-to-equity ratio of 0.46. The firm has a market cap of $9.38 billion, a P/E ratio of 24.74, a P/E/G ratio of 2.01 and a beta of 0.86. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $82.63. The company’s 50-day moving average price is $70.10 and its two-hundred day moving average price is $70.22.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The business had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. During the same quarter last year, the business posted $1.31 earnings per share. Henry Schein’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Activity

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.14% of the company’s stock.

Analyst Upgrades and Downgrades

HSIC has been the topic of several analyst reports. Baird R W upgraded shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Barrington Research restated an “outperform” rating and set a $82.00 price target on shares of Henry Schein in a research note on Friday, September 20th. Robert W. Baird lowered their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, UBS Group cut their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $77.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.